Compare RYAN & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYAN | CRSP |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.9B |
| IPO Year | 2021 | 2016 |
| Metric | RYAN | CRSP |
|---|---|---|
| Price | $35.12 | $52.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 17 |
| Target Price | $50.88 | ★ $70.29 |
| AVG Volume (30 Days) | ★ 2.3M | 1.6M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,051,126,000.00 | $289,590,000.00 |
| Revenue This Year | $15.78 | $807.72 |
| Revenue Next Year | $12.49 | $172.52 |
| P/E Ratio | $86.72 | ★ N/A |
| Revenue Growth | 21.28 | ★ 9169.85 |
| 52 Week Low | $29.28 | $43.53 |
| 52 Week High | $68.53 | $78.48 |
| Indicator | RYAN | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 59.51 | 51.47 |
| Support Level | $30.48 | $50.70 |
| Resistance Level | $38.61 | $59.61 |
| Average True Range (ATR) | 1.54 | 2.87 |
| MACD | 0.45 | -0.08 |
| Stochastic Oscillator | 83.21 | 35.47 |
Ryan Specialty Holdings Inc is an international specialty insurance intermediary providing specialty products, solutions, and services for insurance brokers, agents, and carriers. The company offers wholesale insurance brokerage and delegated underwriting authority products and services, including distribution, underwriting, product development, administration, and risk management. Its expertise spans property, casualty, professional lines, transportation, personal lines, workers compensation, and employee benefits insurance, across traditional insurance and alternative risk solutions. The company operates in the United States and foreign markets, with the majority of revenue generated from the United States.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.